Quick Answer
ELITE PHARMACEUTICALS INC /NV/ reported Operating Income Loss of $19.60 million for the year ending 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed an increase of +81.7% in Operating Income Loss from 2024 to 2025.
- This data is from ELITE PHARMACEUTICALS INC /NV/'s annual report (Form 10-K), filed with the SEC on June 30, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2013: -$1.24 million | Q1 2014: -$2.38 million | Q2 2014: -$4.43 million | Q3 2014: -$4.06 million | Q4 2014: -$2.56 million | Q1 2015: -$5.46 million | Q2 2015: -$2.41 million | Q3 2015: -$3.77 million | Q4 2015: -$2.71 million | Q1 2016: $571.0 thousand | Q2 2016: -$1.24 million | Q3 2016: -$1.21 million | Q4 2016: -$1.72 million | Q1 2017: -$3.19 million | Q2 2017: -$2.24 million | Q3 2017: -$2.13 million | Q4 2017: -$2.06 million | Q1 2018: -$2.62 million | Q2 2018: -$1.86 million | Q3 2018: -$2.65 million | Q4 2018: -$2.64 million | Q2 2019: -$1.15 million | Q3 2019: -$454.5 thousand | Q4 2019: $691.2 thousand | Q2 2020: $830.6 thousand | Q3 2020: $1.34 million | Q4 2020: $1.00 million | Q2 2021: $965.2 thousand | Q3 2021: $1.42 million | Q4 2021: $1.83 million | Q2 2022: $1.02 million | Q3 2022: $1.08 million | Q4 2022: $1.96 million | Q2 2023: $1.60 million | Q3 2023: $1.93 million | Q4 2023: $3.53 million | Q2 2024: $3.86 million | Q3 2024: $3.48 million | Q4 2024: $1.10 million | Q2 2025: $21.70 million | Q3 2025: $8.21 million | Q4 2025: $9.01 million.
- Over the full 15 years of available data (2011 to 2025), ELITE PHARMACEUTICALS INC /NV/'s Operating Income Loss has grown by 2,312.8%.
- Historical annual values: Fiscal year 2025: $19.60 million | Fiscal year 2024: $10.79 million | Fiscal year 2023: $3.68 million | Fiscal year 2022: $5.07 million | Fiscal year 2021: $2.10 million | Fiscal year 2020: -$2.29 million | Fiscal year 2019: -$9.16 million | Fiscal year 2018: -$9.05 million | Fiscal year 2017: -$7.36 million | Fiscal year 2016: -$8.32 million | Fiscal year 2015: -$16.51 million | Fiscal year 2014: -$5.28 million | Fiscal year 2013: -$1.56 million | Fiscal year 2012: -$1.97 million | Fiscal year 2011: -$885.8 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: